Erythromycin treatment for subclinical Ureaplasma urealyticum infection in preterm labor

Fetal Diagn Ther. 1997 Mar-Apr;12(2):89-92. doi: 10.1159/000264438.

Abstract

This study was undertaken to test the effects of erythromycin as an adjunct to tocolysis for preterm labor in women with vaginal cultures positive for Ureaplasma urealyticum. The study group consisted of 18 women in active preterm labor with pregnancies between 26 and 34 weeks of gestation and intact membranes who received 500 mg erythromycin orally every 8 h for 10 days. Seventeen women with similar characteristics served as controls and received no antibiotics. In all women contractions were suppressed with ritodrine. Erythromycin treatment resulted in a statistically significant greater mean delay of delivery (36.4 days) than among the control group (23.1 days). Higher proportion of term pregnancies (7 versus 3 pregnancies), higher mean birth weight (2,745 versus 2,474 g), lower neonatal morbidity (22.2 versus 42.2%) and shorter mean neonatal hospitalization time (9.6 versus 12.1 days) were observed, although these differences were not statistically significant. Adjunctive erythromycin treatment given to women treated for preterm labor with intact membranes and positive vaginal cultures for U. urealyticum appears to prolong gestation and to improve perinatal outcome.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Cohort Studies
  • Erythromycin / administration & dosage
  • Erythromycin / therapeutic use*
  • Female
  • Humans
  • Obstetric Labor, Premature / drug therapy*
  • Obstetric Labor, Premature / microbiology
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / microbiology
  • Pregnancy Outcome
  • Pregnancy Trimester, Third
  • Ureaplasma Infections / drug therapy*
  • Ureaplasma urealyticum* / pathogenicity
  • Vagina / microbiology

Substances

  • Anti-Bacterial Agents
  • Erythromycin